Int J Cancer:前列腺癌细胞中GRB10通过与PP2A互作维持AR活性

2020-10-31 AlexYang MedSci原创

雄激素受体(AR)信号能够驱动前列腺癌(PCa)进展是。不幸的是,雄激素阻断疗法和使用更强效的AR途径抑制剂(ARPIs)并不能起到治愈效果。ARPI耐药(如去势抵抗性PCa,CRPC)将不可避免地发

雄激素受体(AR)信号能够驱动前列腺癌(PCa)进展是。不幸的是,雄激素阻断疗法和使用更强效的AR途径抑制剂(ARPIs)并不能起到治愈效果。ARPI耐药(如去势抵抗性PCa,CRPC)将不可避免地发展。

之前,研究人员证明了GRB10是一个AR转录抑制基因,在功能上有助于CRPC的发展和ARPI耐药。在患者来源的异种移植模型中,研究发现GRB10的表达在CRPC发展前升高,并在临床CRPC样本中显著上调。最近,有研究人员分析了GRB10敲除的PCa细胞的转录组数据,发现AR信号下调。虽然GRB10敲除后AR靶基因的mRNA表达下降,但AR的表达在mRNA或蛋白水平上没有受到影响。进一步研究发现,对AR转录活性至关重要的AR丝氨酸81(S81)的磷酸化水平在GRB10敲除后降低,而过度表达后则增加。GRB10基因敲除细胞的荧光素酶测定也表明AR活性降低。免疫沉淀结合质谱法发现GRB10与PP2A复合物之间存在相互作用,PP2A复合物是已知的AR磷酸酶。进一步的验证和分析表明,GRB10的PH域能够结合到PP2Ac催化亚单位。从机制上看,GRB10敲除后可增加PP2Ac蛋白的稳定性,进而降低AR S81的磷酸化并降低AR活性。

最后,研究人员指出,他们的研究结果表明GRB10和AR信号传导之间存在相互反馈,表明了GRB10在PCa进展中的重要性。

原始出处:

Jun Hao,Xinpei Ci,Yong Wang et al. GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells. Int J Cancer. Oct 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1252742, encodeId=9f1f1252e42d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471668, encodeId=346014e16681d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620271, encodeId=939416202e13c, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896104, encodeId=e82b8961042c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Nov 01 20:27:21 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040880, encodeId=7daa10408800e, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 01 17:04:56 CST 2020, time=2020-11-01, status=1, ipAttribution=)]
    2020-11-03 yxch36
  2. [GetPortalCommentsPageByObjectIdResponse(id=1252742, encodeId=9f1f1252e42d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471668, encodeId=346014e16681d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620271, encodeId=939416202e13c, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896104, encodeId=e82b8961042c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Nov 01 20:27:21 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040880, encodeId=7daa10408800e, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 01 17:04:56 CST 2020, time=2020-11-01, status=1, ipAttribution=)]
    2020-11-03 ylz8405
  3. [GetPortalCommentsPageByObjectIdResponse(id=1252742, encodeId=9f1f1252e42d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471668, encodeId=346014e16681d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620271, encodeId=939416202e13c, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896104, encodeId=e82b8961042c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Nov 01 20:27:21 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040880, encodeId=7daa10408800e, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 01 17:04:56 CST 2020, time=2020-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1252742, encodeId=9f1f1252e42d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471668, encodeId=346014e16681d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620271, encodeId=939416202e13c, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896104, encodeId=e82b8961042c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Nov 01 20:27:21 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040880, encodeId=7daa10408800e, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 01 17:04:56 CST 2020, time=2020-11-01, status=1, ipAttribution=)]
    2020-11-01 ms6000001113694287

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1252742, encodeId=9f1f1252e42d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471668, encodeId=346014e16681d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620271, encodeId=939416202e13c, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Tue Nov 03 05:04:56 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896104, encodeId=e82b8961042c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Nov 01 20:27:21 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040880, encodeId=7daa10408800e, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 01 17:04:56 CST 2020, time=2020-11-01, status=1, ipAttribution=)]
    2020-11-01 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Prostate:去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移

内脏转移(VM)是前列腺癌(PC)的一个重要的不良预后因素,在去势敏感状态下不常见,但在去势抗性产生后经常观察到。然而,VM的部位、出现时间和发生率还未完全阐明。

EBioMedicine:细胞外分泌的烟酰胺磷酸肌转移酶(eNAMPT)在前列腺癌进展中的作用

目前非常需要阻止侵袭性前列腺癌(PCa)的进展。预防侵袭性前列腺癌(PCa)的进展仍然是一个严重的需求。之前的研究表明,细胞外分泌的烟酰胺磷酸肌转移酶(eNAMPT)能够与TLR4结合,是一个具有多功

拜耳的Nubeqa获得NICE支持,用于治疗前列腺癌

Nubeqa(darolutamide)已被授权与雄激素剥夺疗法(ADT)一起使用。根据拜耳的说法,这是NICE在这种适应症中推荐的第一种治疗方法。

Oncogene:去势抵抗性前列腺癌中神经内分泌分化的micromRNA决定因素研究

治疗诱导的神经内分泌前列腺癌(NEPC)是去势抵抗性前列腺癌(CRPC)的一种极具侵袭性的亚型;随着恩杂鲁胺(ENZ)和阿比特龙等高效雄激素受体(AR)通路抑制剂(API)的广泛使用,其发病率越来越高

盘点:近期前列腺癌治疗研究小结

【1】Prostate Cancer P D:恩扎鲁胺和醋酸阿比特龙相关的骨靶向治疗和骨骼相关事件

Lancet:前列腺癌根治术后放疗策略对PSA进程的影响

研究结果不支持前列腺根治术后进行常规辅助放射治疗,辅助放射疗法增加了泌尿系统发病风险。